NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 54.80

-5.1%

12:17 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: david nordic who wrote (228)	5/23/2007 9:09:28 PM
From: david nordic	of 507

Robin CEO started 1/15/07. NKTR is now developing their internal pipeline. Peg Irinotecan is currently in Phase I. In the last webcast, a common was made that NKTR is not seeing patient dropout. Peg process reduced the toxic Irinotecan to near zero. In preclincal tumors in dogs on a 4 wk dosage schedule recorded zero tumor growth. Phase I is scheduled to be completed in Q3. Peg Neulasta is a AMGN/NKTR partnership. NKTR is using off patent compounds in the development of PEGylated and pulmonary technology-based therapeutics. Unlike Roche's Mircera.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next